Get started
Author

Gil D. Fine

Consequences of Delayed Treatment Effects on Analysis of Time-to-Event Endpoints
2007 · Gil D. Fine · Drug Information Journal · 62
Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
2003 · John Lyons, Emel Bayar, et al. · PubMed · 31
Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia
2020 · Joshua F. Zeidner, Daniel J. Lee, et al. · Clinical Cancer Research · 26
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors
2012 · Raoul Tibes, Gil Fine, et al. · Cancer Chemotherapy and Pharmacology · 26
Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients With Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy
2023 · Charles B. Simone, Artur A. Serebrenik, et al. · International Journal of Radiation Oncology*Biology*Physics · 14
PDF
Nonparametric estimation of the receiver operating characteristic curve
1991 · Gil D. Fine · Medical Entomology and Zoology · 9
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
2021 · Joshua F. Zeidner, Tara L. Lin, et al. · Blood Cancer Journal · 7
PDF
Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers
2012 · Gavin Choy, Rajashree Joshi-Hangal, et al. · Cancer Chemotherapy and Pharmacology · 6
Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
2025 · Devalingam Mahalingam, Rachna T. Shroff, et al. · Journal of Clinical Oncology · 5
PDF
Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens.
2011 · K. K. Sankhala, A. W. Tolcher, et al. · Journal of Clinical Oncology · 4
Abstract 2749: MP-470, a dual inhibitor of mutant kinases (c-KIT and PDGFRα) and DNA repair protein Rad 51. Final results from a first-in-man single agent study
2010 · Anthony W. Tolcher, Gavin Choy, et al. · Cancer Research · 4
Abstract CT191: Phase 1, first-in-human, dose-escalation study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients (pts) with advanced solid tumors (ASTs)
2022 · Nicholas J. Vogelzang, Ben George, et al. · Cancer Research · 3
A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly refractory solid tumor patients
2009 · M. M. Mita, A. Tolcher, et al. · Journal of Clinical Oncology · 3
Abstract B209: A self-emulsifying lipid suspension formulation enhances oral bioavailability of MP-470 in a randomized two-way crossover study in healthy male subjects
2009 · Rajashree Joshi-Hangal, Chunlin Tang, et al. · Molecular Cancer Therapeutics · 2
A Formula for Determining Sample Sizes to Study Dose-Response
1997 · Gil D. Fine · Drug Information Journal · 2
Abstract A019: Phase 1, first-in-human, dose-expansion study of oral TP-1287, a cyclin dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma
2022 · Andrew J. Wagner, Gregory M. Cote, et al. · Clinical Cancer Research · 1
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm
2020 · Joshua F. Zeidner, Daniel J. Lee, et al. · Blood · 1
426 POSTER Effects of food on the single-dose pharmacokinetics of oral MP-470 capsules
2008 · J. Kissling, G.D. Fine, et al. · European Journal of Cancer Supplements · 1
Supplementary Appendix from Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia
2023 · Joshua F. Zeidner, Daniel J. Lee, et al.
Data from Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia
2023 · Joshua F. Zeidner, Daniel J. Lee, et al.
Data from Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia
2023 · Joshua F. Zeidner, Daniel J. Lee, et al.
Supplementary Appendix from Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia
2023 · Joshua F. Zeidner, Daniel J. Lee, et al.
Works count: 22
Citation count: 207
H-index: 7
I10-index: 5
Year
Topic
Type